These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 12552938)

  • 1. Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid.
    Jansman FG; Coenen JL; De Graaf JC; Tobi H; Sleijfer DT; Brouwers JR
    Anticancer Res; 2002; 22(6B):3449-55. PubMed ID: 12552938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
    Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
    Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.
    Joulia JM; Pinguet F; Ychou M; Duffour J; Astre C; Bressolle F
    Eur J Cancer; 1999 Feb; 35(2):296-301. PubMed ID: 10448274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles.
    Stutchbury TK; Vine KL; Locke JM; Chrisp JS; Bremner JB; Clingan PR; Ranson M
    Anticancer Drugs; 2011 Jan; 22(1):24-34. PubMed ID: 20881836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
    Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
    Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.
    Guthoff I; Lotspeich E; Fester C; Wallin I; Schatz M; Ehrsson H; Kornmann M
    Anticancer Res; 2003; 23(6D):5203-8. PubMed ID: 14981990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
    Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
    Anticancer Res; 2003; 23(2C):1789-94. PubMed ID: 12820460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
    Siegel-Lakhai WS; Beijnen JH; Vervenne WL; Boot H; Keessen M; Versola M; Koch KM; Smith DA; Pandite L; Richel DJ; Schellens JH
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4495-502. PubMed ID: 17671135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas.
    Kido Y; Okamura T; Tomikawa M; Yamamoto M; Shiraishi M; Okada Y; Kimura T; Sugimachi K
    Cancer; 1996 Oct; 78(8):1794-7. PubMed ID: 8859194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
    Kallen KJ; Hofmann MA; Timm A; Gödderz W; Galle PR; Heike M
    Z Gastroenterol; 2000 Feb; 38(2):153-7. PubMed ID: 10721170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
    Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
    Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU.
    Gamelin EC; Danquechin-Dorval EM; Dumesnil YF; Maillart PJ; Goudier MJ; Burtin PC; Delva RG; Lortholary AH; Gesta PH; Larra FG
    Cancer; 1996 Feb; 77(3):441-51. PubMed ID: 8630950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Beerblock K; Rinaldi Y; André T; Louvet C; Raymond E; Tournigand C; Carola E; Favre R; de Gramont A; Krulik M
    Cancer; 1997 Mar; 79(6):1100-5. PubMed ID: 9070486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.